NasdaqGM - Delayed Quote • USD
CRISPR Therapeutics AG (CRSP)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 18 | 23 | 21 |
| Avg. Estimate | -1.29 | -1.54 | -5.62 | -4.23 |
| Low Estimate | -1.84 | -1.86 | -7.48 | -7.95 |
| High Estimate | 0.8 | -1.02 | -2.63 | 5.08 |
| Year Ago EPS | -0.67 | -0.98 | -1.94 | -5.62 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 23 | 23 |
| Avg. Estimate | 28.11M | 9.88M | 115.03M | 406.2M |
| Low Estimate | -- | -- | 15M | 40M |
| High Estimate | 202.55M | 43.7M | 457.9M | 3.31B |
| Year Ago Sales | 100M | 70M | 371.21M | 115.03M |
| Sales Growth (year/est) | -71.90% | -85.90% | -69.00% | 253.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.7 | -2.12 | -1.95 | -0.07 |
| EPS Actual | -0.67 | -0.98 | -1.41 | 1.1 |
| Difference | 1.03 | 1.14 | 0.54 | 1.17 |
| Surprise % | 60.60% | 53.80% | 27.70% | 1,671.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.29 | -1.54 | -5.62 | -4.23 |
| 7 Days Ago | -1.29 | -1.54 | -5.62 | -4.23 |
| 30 Days Ago | -1.41 | -1.52 | -5.68 | -4.27 |
| 60 Days Ago | -1.46 | -1.56 | -5.78 | -4.26 |
| 90 Days Ago | -1.62 | -1.7 | -5.52 | -3.69 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRSP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -92.50% | -- | -- | 6.50% |
| Next Qtr. | -57.10% | -- | -- | 12.00% |
| Current Year | -189.70% | -- | -- | 5.30% |
| Next Year | 24.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -200.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 4/18/2024 |
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Maintains | Mizuho: Buy to Buy | 3/6/2024 |
| Maintains | Morgan Stanley: Underweight to Underweight | 2/26/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 2/22/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 2/22/2024 |
Related Tickers
NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
VRTX Vertex Pharmaceuticals Incorporated
397.48
-0.06%
EDIT Editas Medicine, Inc.
5.32
+1.92%
BEAM Beam Therapeutics Inc.
21.38
-1.02%
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
BLUE bluebird bio, Inc.
0.9228
+1.13%
DNA Ginkgo Bioworks Holdings, Inc.
0.8601
+10.60%
MRNA Moderna, Inc.
107.97
+1.69%
NVO Novo Nordisk A/S
126.85
+0.84%